Evolution of intravitreal therapy for retinal and macular disorders

Georgios D. Panos

Keywords
Intravitreal injection, age-related macular degeneration, retinal detachment, uveitis, neovascularisation, diabetic retinopathy, diabetic macular oedema, retinal vein occlusion

Macular diseases include a variety of complex pathologies, such as age-related macular degeneration (AMD), diabetic macular oedema (DMO), and macular oedema secondary to retinal vein occlusion (RVO), all of which can lead to potential permanent severe visual loss. Early diagnosis and treatment are essential to prevent blindness and maintain quality of life. In this short historical review, the evolution of modern intravitreal treatment for retinal and macular diseases is presented.

The macula (also known as the macula lutea) is the central area of the retina and consists of cone photoreceptors. Direct exposure of the macula to light provides the centre of the visual field. The structure of the macula must be undisturbed and dry to provide clear images to the brain and maintain good vision. Therefore, any disorder that affects the structure of the macula is considered sight-threatening and must be treated both efficiently and promptly.

During the first decades of the 20th century, the treatment of retinal and macular disorders was relatively conservative and limited to oral or local medication.

In 1920, Jules Gonin in Lausanne, Switzerland performed the first successful treatment of retinal detachment by sealing the retinal break to the underlying retinal pigment epithelium and the choroid. Robert Machemer performed the first pars plana vitrectomy in 1970. Additionally, retinal laser photocoagulation was introduced in the 1950s by Gerhard Meyer-Schwickerath and Hans Littmann of Zeiss Laboratories. In the 1980s and 1990s, intravitreal injections of antibiotics were increasingly used to treat intraocular infections; thus, ophthalmologists became very familiar with intravitreal administration of drugs.

In the 1980s and 1990s, as the acquired immunodeficiency syndrome (AIDS) epidemic unfolded, cytomegalovirus (CMV) infection, along with its most obvious
clinical presentation, CMV retinitis, became the most common opportunistic infection in AIDS patients. These patients were, initially, treated with intravenous ganciclovir, which showed limited therapeutic effect and increased the risk of sepsis because of the required indwelling catheter. In an effort to overcome these limitations, some ophthalmologists began to use intravitreal injections of ganciclovir for CMV retinitis, which were given on a weekly basis due to the short intravitreal half-life. This approach proved highly effective; however, as AIDS-related co-morbidities increased, clinic visits and injections were sometimes missed, leading to suboptimal management. To improve treatment for these patients, a sustained-release ganciclovir implant was developed. The ganciclovir implant was approved by the Food and Drug Administration (FDA) in March 1996; it was significantly more effective, compared with classical systemic treatment, dramatically reducing the incidence of CMV retinitis during the latter half of the 1990s.

Following the ganciclovir implant, a sustained-release fluocinolone drug delivery device was approved by the FDA for the treatment of severe posterior uveitis. This implant was proven to be efficient in patients with persistent DMO, leading to complete resolution of the fluid in some cases; this effect had not been previously observed. This observation showed the potential therapeutic effect of steroids for cases of DMO and led ophthalmologists to begin injecting triamcinolone into the vitreous cavity with excellent results, which were later confirmed by randomized clinical trials. The use of intravitreal triamcinolone was later expanded to include RVO-related cystoid macular oedema (CMO), uveitic macular oedema, and Irvine-Gass Syndrome.

In the 1990s, several studies showed that vascular endothelial growth factor (VEGF) was present at high levels in the neovascular membranes of patients with wet AMD and that drugs which could inhibit VEGF might provide a possible treatment for choroidal neovascularisation. In 2004, Pegaptanib (Eyetech Pharmaceuticals and Pfizer) became the first anti-VEGF agent to receive approval by the FDA for the treatment of neovascular AMD. Soon after, bevacizumab (Genentech and Roche) was approved for cancer therapy; given the role of VEGF in wet AMD, intravenous and later intravitreal administration of bevacizumab was offered to patients with neovascular AMD as off-label treatment. Ranibizumab (Genentech and Novartis), a humanized monoclonal anti-Fab antibody that binds with high affinity to VEGF-A and inhibits all of its biologically active isoforms, was found to be an effective and safe treatment for neovascular AMD in two pivotal trials, Minimally Classic/Occult Trial of the Anti-VEGF Antibody Ranibizumab in the Treatment of Neovascular Age-Related Macular Degeneration (MARINA) and Anti-VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in AMD (ANCHOR) in 2006. Based on this evidence, ranibizumab received FDA approval the same year and became the gold standard for the treatment of wet AMD. In the 2010s, a number of trials showed that ranibizumab was also an effective treatment for other macular diseases, including DMO and RVO-related CMO. Concurrently, Ozurdex (dexamethasone intravitreal implant releasing steroid continuously over a 3–6 month period), developed by Allergan Inc., received FDA approval for the treatment of macular oedema secondary to central and branch RVO. Clinical trials showed that Ozurdex is also an efficient treatment for DMO, non-infectious intermediate and posterior uveitis, and postoperative macular oedema. Today, Ozurdex implant is mainly used as first-line treatment for macular oedema secondary to diabetes.
and RVO or second-line treatment when anti-VEGF agents fail, especially in pseudophakic patients and patients without history of glaucoma, as steroids will accelerate cataract progression and can eventually increase intraocular pressure.44,45

In 2011, the FDA approved aflibercept/VEGF trap (Bayer HealthCare, Inc., and Regeneron Pharmaceutical, Inc.), a recombinant fusion protein that inhibits VEGF-A, VEGF-B, and placental growth factor, for the treatment of neovascular AMD.46 The most important advantage of aflibercept, compared with ranibizumab and bevacizumab, is the need for less-frequent injections.47–49 VEGF trap was also found to be an efficient treatment for DMO and RVO-related CMO, showing better functional improvement in cases with worse visual acuity at baseline, compared with ranibizumab and bevacizumab.50–53 In 2014, Iluvien (intravitreal implant releasing fluocinolone acetonide for 36 months), developed by Alimera, received FDA approval for DMO and has been shown to be effective for patients who have persistent or recurrent macular oedema, despite previous multiple and frequent anti-VEGF injections.54,55 Recently, brolucizumab, a new anti-VEGF agent for the treatment of wet AMD (developed by Alcon Laboratories, Inc.), has been found to be comparable to aflibercept, with better anatomical results.56 Larger studies in this field, especially regarding the efficacy of the newer anti-VEGF drug, brolucizumab, are expected with great interest.

Declaration of conflicting interest
The authors declare that there is no conflict of interest.

Funding
This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

ORCID iD
Georgios D. Panos http://orcid.org/0000-0001-8399-7456

References
1. Rehman I and Bhimji SS. Anatomy, Head, Eye. Treasure Island: StatPearls, 2018.
2. Wolfensberger TJ. Jules Gonin. Pioneer of retinal detachment surgery. Indian J Ophthalmol 2003; 51: 303–308.
3. Machemer R, Buettner H, Norton EW, et al. Vitrectomy: a pars plana approach. Trans Am Acad Ophthalmol Otolaryngol 1971; 75: 813–820.
4. Kozak I and Luttrull JK. Modern retinal laser therapy. Saudi J Ophthalmol 2015; 29: 137–146.
5. Results of the Endophthalmitis Vitrectomy Study. A randomized trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis. Endophthalmitis Vitrectomy Study Group. Arch Ophthalmol 1995; 113: 1479–1496. doi:10.1001/archopht.1995.01100120009001
6. Baum J, Peyman GA and Barza M. Intravitreal administration of antibiotic in the treatment of bacterial endophthalmitis. III. Consensus. Surv Ophthalmol 1982; 26: 204–206. doi:10.1016/0039-6257(82)90080-7
7. Hoover DR, Saah AJ, Bacellar H, et al. Clinical manifestations of AIDS in the era of pneumocystis prophylaxis. Multicenter AIDS cohort study. N Engl J Med 1993; 329: 1922–1926.
8. Henry K, Cantrill H, Fletcher C, et al. Use of intravitreal ganciclovir (dihydroxy propoxymethyl guanine) for cytomegalovirus retinitis in a patient with AIDS. Am J Ophthalmol 1987; 103: 17–23.
9. Ussery FM, 3rd, Gibson SR, Conklin RH, et al. Intravitreal ganciclovir in the treatment of AIDS-associated cytomegalovirus retinitis. Ophthalmology 1988; 95: 640–648.
10. Sanborn GE, Anand R, Torti RE, et al. Sustained-release ganciclovir therapy for treatment of cytomegalovirus retinitis. Use of an intravitreal device. Arch Ophthalmol 1992; 110: 188–195.
11. Smith TJ, Pearson PA, Blandford DL, et al. Intravitreal sustained-release ganciclovir. *Arch Ophthalmol* 1992; 110: 255–258.

12. Martin DF, Kuppermann BD, Wolitz RA, et al. Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group. *N Engl J Med* 1999; 340: 1063–1070.

13. Martin DF, Parks DJ, Mellow SD, et al. Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant. A randomized controlled clinical trial. *Arch Ophthalmol* 1994; 112: 1531–1539.

14. Musch DC, Martin DF, Gordon JF, et al. Treatment of cytomegalovirus retinitis with a sustained-release ganciclovir implant. The Ganciclovir Implant Study Group. *N Engl J Med* 1997; 337: 83–90.

15. Palella FJ, Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. *N Engl J Med* 1998; 338: 853–860.

16. Callanan DG, Jaffe GJ, Martin DF, et al. Treatment of posterior uveitis with a fluocinolone acetonide implant: three-year clinical trial results. *Arch Ophthalmol* 2008; 126: 1191–1201.

17. Jaffe GJ, Martin D, Callanan D, et al. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. *Ophthalmology* 2006; 113: 1020–1027.

18. Multicenter Uveitis Steroid Treatment Trial Research Group, Kempen JH, Altaweeel MM, et al. Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial. *Ophthalmology* 2011; 118: 1916–1926. doi:10.1016/j.ophtha.2011.07.027

19. Pearson PA, Abou-Jaoude ES, Smith TJ, et al. A phase I evaluation of sustained delivery fluocinolone in the treatment of diabetic macular edema (DME). American Academy of Ophthalmology. Dallas, TX, 2000.

20. Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. *Ophthalmology* 2008; 115: 1447–1449, 1449 e1–10. doi:10.1016/j.ophtha.2008.06.015

21. Diabetic Retinopathy Clinical Research Network, Elman MJ, Aiello LP, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. *Ophthalmology* 2010; 117: 1064–1077 e35.

22. Conway MD, Canakis C, Livir-Rallatos C, et al. Intravitreal triamcinolone acetonide for refractory chronic pseudophakic cystoid macular edema. *J Cataract Refract Surg* 2003; 29: 27–33.

23. Ip MS, Scott IU, VanVeldhuisen PC, et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. *Arch Ophthalmol* 2009; 127: 1101–1114. doi:10.1001/archophthalmol.2009.234

24. Antcliff RJ, Spalton DJ, Stanford MR, et al. Intravitreal triamcinolone for uveitic cystoid macular edema: an optical coherence tomography study. *Ophthalmology* 2001; 108: 765–772.

25. Frank RN, Amin RH, Eliott D, et al. Basic fibroblast growth factor and vascular endothelial growth factor are present in epiretinal and choroidal neovascular membranes. *Am J Ophthalmol* 1996; 122: 393–403.

26. Lopez PF, Sippy BD, Lambert HM, et al. Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. *Invest Ophthalmol Vis Sci* 1996; 37: 855–868.

27. Miller JW, Adamis AP, Shima DT, et al. Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. *Am J Pathol* 1994; 145: 574–584.
28. New drug treats age-related macular degeneration. *FDA Consum* 2005; 39: 4.
29. New treatments for colorectal cancer. *FDA Consum* 2004; 38: 17.
30. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. *N Engl J Med* 2006; 355: 1432–1444.
31. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. *N Engl J Med* 2006; 355: 1419–1431.
32. Treatment for wet macular degeneration. *FDA Consum* 2006; 40: 6.
33. Chappelow AV and Kaiser PK. Neovascular age-related macular degeneration: potential therapies. *Drugs* 2008; 68: 1029–1036.
34. Campochiaro PA, Sophie R, Pearlman J, et al. Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study. *Ophthalmology* 2014; 121: 209–219.
35. Varma R, Bressler NM, Suner I, et al. Improved vision-related function after ranibizumab for macular edema after retinal vein occlusion: results from the BRAVO and CRUISE trials. *Ophthalmology* 2012; 119: 2108–2118.
36. Brown DM, Nguyen QD, Marcus DM, et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. *Ophthalmology* 2013; 120: 2013–2022.
37. Massin P, Bandello F, Garweg JG, et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. *Diabetes Care* 2010; 33: 2399–2405.
38. Triantafylla M, Massa HF, Dardabounis D, et al. Ranibizumab for the treatment of degenerative ocular conditions. *Clin Ophthalmol* 2014; 8: 1187–1198.
39. Bansal R, Bansal P, Kulkarni P, et al. Wandering Ozurdex(R) implant. *J Ophthalmic Inflamm Infect* 2012; 2: 1–5.
40. Haller JA, Bandello F, Belfort R, Jr, et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. *Ophthalmology* 2010; 117: 1134–1146 e3.
41. Lowder C, Belfort R, Jr, Lightman S, et al. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. *Arch Ophthalmol* 2011; 129: 545–553.
42. Williams GA, Haller JA, Kuppermann BD, et al. Dexamethasone posterior-segment drug delivery system in the treatment of macular edema resulting from uveitis or Irvine-Gass syndrome. *Am J Ophthalmol* 2009; 147: 1048–1054, 1054 e1–2.
43. Scaramuzzi M, Querques G, Spina CL, et al. Repeated intravitreal dexamethasone implant (Ozurdex) for diabetic macular edema. *Retina* 2015; 35: 1216–1222.
44. Garweg JG and Zandi S. Retinal vein occlusion and the use of a dexamethasone intravitreal implant (Ozurdex(R)) in its treatment. *Graefes Arch Clin Exp Ophthalmol* 2016; 254: 1257–1265.
45. Khan Z, Kuriakose RK, Khan M, et al. Efficacy of the intravitreal sustained-release dexamethasone implant for diabetic macular edema refractory to anti-vascular endothelial growth factor therapy: meta-analysis and clinical implications. *Ophthalmic Surg Lasers Imaging Retina* 2017; 48: 160–166.
46. Zhang Y, Chioreso C, Schweizer ML, et al. Effects of aflibercept for neovascular age-related macular degeneration: a systematic review and meta-analysis of observational comparative studies. *Invest Ophthalmol Vis Sci* 2017; 58: 5616–5627.
47. Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. *Ophthalmology* 2012; 119: 2537–2548.
48. Verner-Cole EA, Davis SJ and Lauer AK. Aflibercept for the treatment of neovascular age-related macular degeneration. *Drugs Today (Barc)* 2012; 48: 317–329.
49. Semeraro F, Morescalchi F, Duse S, et al. Aflibercept in wet AMD: specific role and optimal use. *Drug Des Devel Ther* 2013; 7: 711–722.
50. Keating GM. Aflibercept: A review of its use in diabetic macular oedema. *Drugs* 2015; 75: 1153–1160. doi:10.1007/s40265-015-0421-y
51. Diabetic Retinopathy Clinical Research Network, Wells JA, Glassman AR, et al.
Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. *N Engl J Med* 2015; 372: 1193–1203. doi:10.1056/NEJMoa1414264

52. Pielen A, Clark WL, Boyer DS, et al. Integrated results from the COPERNICUS and GALILEO studies. *Clin Ophthalmol* 2017; 11: 1533–1540.

53. Hoy SM. Aflibercept: A review in macular oedema secondary to branch retinal vein occlusion. *Drugs Aging* 2017; 34: 393–400.

54. Saedon H, Anand A and Yang YC. Clinical utility of intravitreal fluocinolone acetonide (Iluvien(R)) implant in the management of patients with chronic diabetic macular edema: a review of the current literature. *Clin Ophthalmol* 2017; 11: 583–590.

55. Syed YY. Fluocinolone Acetonide Intravitreal Implant 0.19 mg (ILUVIEN (R)): A Review in Diabetic Macular Edema. *Drugs* 2017; 77: 575–583. doi:10.1007/s40265-017-0722-4

56. Dugel PU, Jaffe GJ, Sallstig P, et al. Brolucizumab versus aflibercept in participants with neovascular age-related macular degeneration: A randomized trial. *Ophthalmology* 2017; 124: 1296–1304. doi:10.1016/j.ophtha.2017.03.057